These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31828376)

  • 1. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
    Dou L; Hou C; Ma C; Li F; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
    Ann Hematol; 2020 Jan; 99(1):167-179. PubMed ID: 31828376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
    Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
    Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
    Dou L; Wang L; Li X; Liu Y; Li F; Wang L; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
    Medicine (Baltimore); 2021 Feb; 100(8):e24725. PubMed ID: 33663084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
    Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
    Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
    Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.
    Yang J; Jiang J; Cai Y; Li S; Wan L; Zhu J; Liu H; Shao S; Bai H; Wang C; Song X
    Bone Marrow Transplant; 2019 Jul; 54(7):1049-1057. PubMed ID: 30446741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
    Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
    Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies.
    Fang S; Wang N; Wang L; Du J; Yang J; Wen Y; Wei Y; Qian K; Wang H; Jiao Y; Gao C; Dou L
    Ann Transplant; 2022 Oct; 27():e937356. PubMed ID: 36217289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies.
    Du Y; Zhang Y; Xu X; Cai Y; Wei Y; Huang C; Yang J; Qiu H; Niu J; Zhou K; Xia X; Shen C; Tong Y; Dong B; Wan L; Song X
    Ann Hematol; 2024 Sep; 103(9):3765-3774. PubMed ID: 38981923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies.
    Li HH; Li F; Gao CJ; Huang WR; Bo J; Dou LP; Wang LL; Jing Y; Wang L; Li WJ; Yu L; Liu DH
    Br J Haematol; 2017 Jan; 176(1):92-100. PubMed ID: 27714774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients Beyond the Optimal Range of rATG-AUC Still Benefit from the Targeted Dosing Strategy in Unmanipulated Haplo-PBSCT.
    Du J; Zhang H; Wang H; Luan S; Chen S; Li F; Wang L; Dou L; Liu D
    Transplant Cell Ther; 2024 Oct; 30(10):1023.e1-1023.e12. PubMed ID: 39111369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.